China SXT Pharmaceuticals (NASDAQ:SXTC) Releases Earnings Results

China SXT Pharmaceuticals (NASDAQ:SXTC) released its quarterly earnings results on Wednesday. The company reported ($0.03) earnings per share for the quarter, FiscalAI reports. The business had revenue of $0.31 million during the quarter.

China SXT Pharmaceuticals Stock Up 13.5%

SXTC stock traded up $0.19 during trading on Wednesday, reaching $1.60. 252,988 shares of the stock were exchanged, compared to its average volume of 1,249,133. The company has a quick ratio of 3.40, a current ratio of 3.54 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $1.42 and its 200 day moving average is $1.57. China SXT Pharmaceuticals has a twelve month low of $0.95 and a twelve month high of $7.84.

Hedge Funds Weigh In On China SXT Pharmaceuticals

An institutional investor recently raised its position in China SXT Pharmaceuticals stock. Virtu Financial LLC boosted its holdings in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) by 107.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,983 shares of the company’s stock after purchasing an additional 15,013 shares during the period. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.02% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of China SXT Pharmaceuticals in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, China SXT Pharmaceuticals presently has a consensus rating of “Sell”.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.